Jubilant's Q3 sales flat but order book healthy
This article was originally published in Scrip
Jubilant Life Sciences, India's largest custom research and manufacturing services company, has reported a marginal rise in net sales for the third quarter ended 31 December, to Rs8.67 billion ($193.9 million), compared with Rs8.65 billion from the same line of business prior to a restructuring last year.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.